NDA 018961 · Hospira
Chromic Chloride In Plastic Container
Chromic Chloride · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 12, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jun 26, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
861
472 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 24, 2026.
INDICATIONS AND USAGE Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
- CHROMIC CHLORIDE IN PLASTIC CONTAINER · CHROMIC CHLORIDE EQ 0.004MG CHROMIUM/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Chromic Chloride" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue101
- nausea88
- diarrhoea82
- headache72
- pain66
- drug ineffective65
- dizziness54
- arthralgia53
- asthenia52
- weight decreased51
- insomnia48
- fall45
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 27 |
| 2005 | 16 |
| 2006 | 17 |
| 2007 | 18 |
| 2008 | 22 |
| 2009 | 23 |
| 2010 | 10 |
| 2011 | 7 |
| 2012 | 21 |
| 2013 | 33 |
| 2014 | 45 |
| 2015 | 78 |
| 2016 | 74 |
| 2017 | 64 |
| 2018 | 64 |
| 2019 | 51 |
| 2020 | 64 |
| 2021 | 38 |
| 2022 | 39 |
| 2023 | 45 |
| 2024 | 40 |
| 2025 | 30 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia.
Anderson RA, Polansky MM, Bryden NA, et al. · Metabolism 1987 · Clinical Trial, Controlled Clinical Trial
- Urinary chromium excretion of human subjects: effects of chromium supplementation and glucose loading.
Anderson RA, Polansky MM, Bryden NA, et al. · Am J Clin Nutr 1982 · Clinical Trial, Comparative Study
- Gastrointestinal protein loss in rheumatoid arthritis, studied with 51Cr-chromic chloride and 125I albumin.
Plantin LO, Strandberg O · Scand J Rheumatol 1974 · Clinical Trial
- The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects.
Offenbacher EG, Rinko CJ, Pi-Sunyer FX · Am J Clin Nutr 1985 · Clinical Trial, Controlled Clinical Trial
- Serum chromium of human subjects: effects of chromium supplementation and glucose.
Anderson RA, Bryden NA, Polansky MM · Am J Clin Nutr 1985 · Clinical Trial, Controlled Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.